论文部分内容阅读
食管胃结合部腺癌(AEG)的发病率呈持续上升趋势,尤其是在西方国家,增长速度远远高于东方国家。对于SiewertI型AEG,其生物学特性和外科治疗方案更接近于食管癌;对于SiewertⅡ、Ⅲ型AEG,外科治疗方案更接近于胃癌。目前有两个大型的Ⅲ期临床试验比较了不同术式的效果:SiewertI型AEG建议采用经胸切除的手术;而SiewertⅡ、Ⅲ型肿瘤建议采用开腹经食管裂孔的术式。同时,围手术期化疗、化放疗的作用也在临床试验中得到了进一步证实。
The incidence of esophagogastric junctional adenocarcinoma (AEG) is on an upward trend, especially in western countries, where the growth rate is much higher than in the East. For SiewertI type AEG, its biological characteristics and surgical treatment of more close to esophageal cancer; for Siewert Ⅱ, Ⅲ AEG, surgical treatment is more similar to gastric cancer. There are currently two large phase III trials comparing different surgical procedures: SiewertI type AEG is recommended for transthoracic surgery, and Siewert type II and III tumors are recommended for laparotomy. At the same time, the role of perioperative chemotherapy and chemoradiation has been further confirmed in clinical trials.